March 03, 2020
Genentech was on the receiving end of an upbraiding Tuesday after the Federal Circuit sensed the biotech giant had come down too harshly on the Delaware federal judge who denied its bid to block a biosimilar of a blockbuster cancer drug.
July 22, 2019
Amgen and Allergan have started selling their biosimilar versions of Genentech's blockbuster cancer treatments Avastin and Herceptin in the U.S., announcing the launch immediately after a Delaware federal judge refused to block the sales.